Evidence map›Paper›PMID 42536138›Full record

ArticleMolecular and cellular biochemistry2026

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation.

Mathieu Césaire, Kilian Lecrosnier, Juliette Montanari, Mateusz Sitarz, Sahra Messaoudi, Elisabeth Chartier-Garcia, Isabelle Testard, Guénaëlle Levallet, François Christy, Serge Candéias and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mathieu CésaireCentre de recherche sur les Ions les Matériaux et la Photonique, Université de Caen Normandie, CEA, CNRS, ENSICAEN, Normandy University, Team Applications in Radiobiology with Accelerated Ions, UMR6252 CIMAP, Bd Becquerel, 14000, Caen, France. m.cesaire@baclesse.unicancer.fr.
Kilian LecrosnierCentre de recherche sur les Ions les Matériaux et la Photonique, Université de Caen Normandie, CEA, CNRS, ENSICAEN, Normandy University, Team Applications in Radiobiology with Accelerated Ions, UMR6252 CIMAP, Bd Becquerel, 14000, Caen, France.
Juliette MontanariCentre de recherche sur les Ions les Matériaux et la Photonique, Université de Caen Normandie, CEA, CNRS, ENSICAEN, Normandy University, Team Applications in Radiobiology with Accelerated Ions, UMR6252 CIMAP, Bd Becquerel, 14000, Caen, France.
Mateusz SitarzCentre de recherche sur les Ions les Matériaux et la Photonique, Université de Caen Normandie, CEA, CNRS, ENSICAEN, Normandy University, Team Applications in Radiobiology with Accelerated Ions, UMR6252 CIMAP, Bd Becquerel, 14000, Caen, France.
Sahra MessaoudiBioTICLA Laboratory, Normandy University, UNICAEN, INSERM U1086 ANTICIPE, Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, 14076, Caen, France.
Elisabeth Chartier-GarciaUniversity Grenoble Alpes, CEA, CNRS, UMR5249 IRIG-LCBM, 17 avenue des Martyrs, Grenoble, 38054, France.
Isabelle TestardUniversity Grenoble Alpes, CEA, CNRS, UMR5249 IRIG-LCBM, 17 avenue des Martyrs, Grenoble, 38054, France.
Guénaëlle LevalletNormandy University, UNICAEN, CNRS, UMR6030 ISTCT, GIP Cyceron, Caen, 14000, France.
François ChristyDepartment of Clinical Research, Comprehensive Cancer Center François Baclesse, Caen, France.
Serge CandéiasUniversity Grenoble Alpes, CEA, CNRS, UMR5249 IRIG-LCBM, 17 avenue des Martyrs, Grenoble, 38054, France.
François ChevalierCentre de recherche sur les Ions les Matériaux et la Photonique, Université de Caen Normandie, CEA, CNRS, ENSICAEN, Normandy University, Team Applications in Radiobiology with Accelerated Ions, UMR6252 CIMAP, Bd Becquerel, 14000, Caen, France. francois.chevalier@ganil.fr.ORCID https://orcid.org/0000-0002-8488-2324

Funding

Électricité de France committee « Protection de l'Homme et de l'Environnement (CPPHE) », under the Life Sciences group of the four-way national agreement CEA-EDF-IRSN-Framatome, "Rôle de KRAS dans la modulation de la radiorésistance et du statut inflammatoire dans le cancer bronchique non à petites cellulesGRAL ANR-17-EURE-0003LabEx PRIMES ANR-11-LABX-0063Ligue Contre le Cancer 2022-2023, « Traitement par inhibiteurs de KRAS en association avec l'irradiation X vs ions carbone dans le cancer bronchique non à petite cellule (CBNPC) avec mutation KRAS »
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) with KRAS

Indexed as

Carcinoma, Non-Small-Cell LungHeavy Ion RadiotherapyLung NeoplasmsMutationProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyrimidinesRadiation-Sensitizing AgentsRadiation ToleranceA549 CellsCell Line, TumorHumansPiperazinesPyridinesKRAS protein, humanPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridinesPyrimidinesRadiation-Sensitizing AgentssotorasibCarbon ions irradiationKRAS inhibitorNon-small cell lung cancer

Identifiers

PMID42536138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.